Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

Search

Research

Systematic review and meta-analysis of respiratory viral coinfections in children

Coinfection is not associated with increased clinical severity, but further investigations by pathogen pairs are warranted

Research

Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease

Invasive fungal disease (IFD) remains a challenging complication of treatment for paediatric acute leukaemia. Consensus fungal treatment guidelines recommend withholding chemotherapy to facilitate immune recovery in this setting, yet prolonged delays in leukaemia therapy increase risk of relapse.

Research

Moort Vax Waangkiny: Understanding reasons for routine vaccine uptake among Aboriginal children aged <5 years in Perth (Boorloo) metro

Aboriginal children aged younger than 5 years in Perth (Boorloo) have lower vaccine uptake compared to non-Aboriginal children.

Research

Australian Group on Antimicrobial Research surveillance outcome programs - bloodstream infections and antimicrobial resistance patterns from patients less than 18 years of age

From 1 January 2020 to 31 December 2021, thirty-eight institutions across Australia submitted data to the Australian Group on Antimicrobial Resistance (AGAR) from patients aged < 18 years (AGAR-Kids). Over the two years, 1,679 isolates were reported from 1,611 patients. This AGAR-Kids report aims to describe the population of children and adolescents with bacteraemia reported to AGAR and the proportion of resistant isolates.

Research

Paediatric Active Enhanced Diseases Surveillance (PAEDS)

PAEDS monitors for key vaccine preventable conditions and severe side effects from vaccine in 5 paediatric hospitals in Australia.

Research

The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster

PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. We report data for second boosters among individuals 50-<70 years old primed with AZD1222 (50-<70y-AZD1222) until Day 84.

Research

Characterising the epidemiology of RSV in Australian children through record linkage: clinical burden, outcomes and risk factors

Hannah Peter Moore Richmond OAM BSc (Hons) GradDipClinEpi PhD MBBS MRCP(UK) FRACP Program Head, Infection and Vaccines Head, Vaccine Trials Group 08

Research

CORONAVAX – Preparing Community and Government

Christopher Blyth MBBS (Hons) DCH FRACP FRCPA PhD Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases

Research

Determining the off-target effects of infant vaccines on respiratory infection outcomes in Western Australian children

Christopher Hannah Lea-Ann Blyth Moore Kirkham MBBS (Hons) DCH FRACP FRCPA PhD OAM BSc (Hons) GradDipClinEpi PhD PhD Centre Head, Wesfarmers Centre

Research

FluCAN - The Influenza Complications Alert Network

The main aim of the study is to provide timely surveillance data to public health authorities on severe influenza.